Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo de estudio
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Biopharm Drug Dispos ; 31(5-6): 278-85, 2010 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-20578213

RESUMEN

The present study explored the feasibility of a differential setup for the in situ perfusion technique with mesenteric cannulation in rats to assess drug interactions at the level of intestinal absorption. In contrast to the classic, parallel in situ perfusion setup, the differential approach aims to identify intestinal drug interactions in individual animals by exposing the perfused segment to a sequence of multiple conditions. First, the setup was validated by assessing the interaction between the P-glycoprotein (P-gp) inhibitor verapamil and the transport probes atenolol (paracellular transport), propranolol (transcellular) and talinolol (P-gp mediated efflux). While transport of atenolol and propranolol remained constant for the total perfusion time (2 h), a verapamil-induced increase in talinolol transport was observed within individual rats (between 3.2- and 5.2-fold). In comparison with the parallel setup, the differential in situ perfusion approach enhances the power to detect drug interactions with compounds that exhibit strong subject-dependent permeability. This was demonstrated by identifying an interaction between amprenavir and ketoconazole (P-gp and CYP3A inhibitor) in five out of seven rats (permeability increase between 1.9- and 4.2-fold), despite high inter-individual differences in intrinsic permeability for amprenavir. In combination with an increased throughput (up to 300%) and a reduced animal use (up to 50%), the enhanced power of the differential approach improves the utility of the biorelevant in situ perfusion technique with mesenteric blood sampling to elucidate the intestinal interaction profile of drugs and drug candidates.


Asunto(s)
Interacciones Farmacológicas , Absorción Intestinal/efectos de los fármacos , Perfusión/métodos , Circulación Esplácnica/efectos de los fármacos , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/antagonistas & inhibidores , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/efectos de los fármacos , Antagonistas Adrenérgicos beta/sangre , Antagonistas Adrenérgicos beta/farmacocinética , Animales , Carbamatos/sangre , Carbamatos/farmacocinética , Furanos , Cetoconazol/sangre , Cetoconazol/farmacocinética , Masculino , Polietilenglicoles/farmacocinética , Ratas , Ratas Wistar , Sulfonamidas/sangre , Sulfonamidas/farmacocinética , Verapamilo/sangre , Verapamilo/farmacocinética , Vitamina E/análogos & derivados , Vitamina E/sangre , Vitamina E/farmacocinética
2.
Anal Biochem ; 172(2): 495-8, 1988 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-3189791

RESUMEN

Ketoconazole, cis-1-acetyl-4-[4[[2-(2,4-dichlorophenyl)-2-(1H-imidazol- 1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine, a clinically used antifungal agent, is also an inhibitor of steroid hormone biosynthesis. A high-performance liquid chromatographic method is described which resolves ketoconazole with selectivity and high sensitivity provided by the use of electrochemical detection. Ketoconazole can be detected in high-performance liquid chromatography by electrochemical oxidation at a glassy carbon electrode at a potential of +1.0 V. Electrochemical detection offers improved sensitivity and selectivity over ultraviolet absorbance or fluorescence detection after derivatization. The method utilizes a volatile buffer system compatible with postcolumn analyses and an internal standard which is electrochemically active. This technique provides a simple method to assay ketoconazole. Ketoconazole can be detected in human plasma and saliva after a single oral therapeutic dose.


Asunto(s)
Cromatografía Líquida de Alta Presión , Cetoconazol/análisis , Saliva/análisis , Electroquímica , Cetoconazol/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA